These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26654975)

  • 1. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment.
    Sorrentino S; De Rosa S; Ambrosio G; Mongiardo A; Spaccarotella C; Polimeni A; Sabatino J; Torella D; Caiazzo G; Indolfi C
    BMC Cardiovasc Disord; 2015 Dec; 15():169. PubMed ID: 26654975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is high pressure postdilation safe in bioresorbable vascular scaffolds? Optical coherence tomography observations after noncompliant balloons inflated at more than 24 atmospheres.
    Fabris E; Caiazzo G; Kilic ID; Serdoz R; Secco GG; Sinagra G; Lee R; Foin N; Di Mario C
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):839-46. PubMed ID: 26370357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance.
    Mattesini A; Secco GG; Dall'Ara G; Ghione M; Rama-Merchan JC; Lupi A; Viceconte N; Lindsay AC; De Silva R; Foin N; Naganuma T; Valente S; Colombo A; Di Mario C
    JACC Cardiovasc Interv; 2014 Jul; 7(7):741-50. PubMed ID: 25060016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
    Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
    BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct bioresorbable vascular scaffold implantation: Feasibility and midterm results.
    Suárez de Lezo J; Martín P; Mazuelos F; Nóvoa J; Ojeda S; Pan M; Segura J; Hernández E; Romero M; Melián F; Medina A; Suárez de Lezo J
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):E173-82. PubMed ID: 26268440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture of Bioresorbable Vascular Scaffold After Side-Branch Balloon Dilation in Bifurcation Coronary Narrowings.
    Pan M; Romero M; Ojeda S; Suarez de Lezo J; Segura J; Mazuelos F; Martin P; Medina A; Suarez de Lezo J
    Am J Cardiol; 2015 Oct; 116(7):1045-9. PubMed ID: 26243578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioresorbable Scaffold for Treatment of Coronary Artery Lesions: Intravascular Ultrasound Results From the ABSORB Japan Trial.
    Okada K; Honda Y; Kitahara H; Otagiri K; Tanaka S; Hollak MB; Yock PG; Popma JJ; Kusano H; Cheong WF; Sudhir K; Fitzgerald PJ; Kimura T;
    JACC Cardiovasc Interv; 2018 Apr; 11(7):648-661. PubMed ID: 29622143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine use of optical coherence tomography in bioresorbable vascular scaffold implantation: insights on technique optimization and long-term outcomes.
    Abdelaziz HK; Abuomara HZ; Ali MH; Eichhofer J; Patel B; Saad M
    Coron Artery Dis; 2019 Jun; 30(4):263-269. PubMed ID: 30883433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does optimal lesion preparation reduce the amount of acute recoil of the Absorbe BVS? Insights from a real-world population.
    Danzi GB; Sesana M; Arieti M; Villa G; Rutigliano S; Aprile A; Nicolino A; Moshiri S; Valenti R
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):984-91. PubMed ID: 26268401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry.
    Naganuma T; Colombo A; Lesiak M; Capodanno D; Gori T; Nef H; Caramanno G; Naber C; Di Mario C; Ruparelia N; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Kawamoto H; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Latib A
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):47-56. PubMed ID: 27414021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing.
    Džavík V; Colombo A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):81-8. PubMed ID: 24332424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the GHOST-EU registry.
    Baquet M; Nef H; Gori T; Latib A; Capodanno D; Di Mario C; Sabate M; Colombo A; Tamburino C; Mehilli J
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):276-282. PubMed ID: 29171715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes.
    Kochman J; Tomaniak M; Pietrasik A; Kołtowski Ł; Rdzanek A; Huczek Z; Mazurek T; Jąkała J; Ząbek A; Legutko J; Kochman W; Filipiak KJ
    Cardiol J; 2015; 22(3):315-22. PubMed ID: 25428734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary artery perforation at the level of two-overlapping bioresorbable vascular scaffolds: The importance of vessel sizing and scaffold thickness.
    Pichette M; Chevalier F; Généreux P
    Catheter Cardiovasc Interv; 2015 Oct; 86(4):686-91. PubMed ID: 26122768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions.
    Tanaka A; Jabbour RJ; Mitomo S; Latib A; Colombo A
    JACC Cardiovasc Interv; 2017 Mar; 10(6):539-547. PubMed ID: 28335892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
    Onuma Y; Serruys PW; Gomez J; de Bruyne B; Dudek D; Thuesen L; Smits P; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia H; Ormiston JA;
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):3-12. PubMed ID: 21413120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.